Oppenheimer analyst Jay Olson raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $89.00 (from $80.00) while maintaining an ...
This is a premium only article. To continue reading this article and more like it please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
